GLP1-TZ is a synthetic analog of gastric inhibitory polypeptide (GIP), possessing dual functionality by interacting with both GIP and glucagon-like peptide-1 (GLP-1) receptors. Laboratory research has extensively explored GLP1-TZ for its potential roles in glucose metabolism, insulin secretion, and appetite modulation. Studies indicate that GLP1-TZ may influence insulin release, enhance insulin sensitivity, and affect satiety signaling pathways.

Scientific investigations are also examining potential interactions of GLP1-TZ with cardiovascular health pathways and metabolic processes related to conditions such as non-alcoholic fatty liver disease (NAFLD). Further laboratory research is exploring its possible impacts on adipokine profiles, including modulation of adiponectin levels.

Important Notice: This product is intended strictly for research purposes only. It is not approved by the FDA and is not intended for human or animal consumption, nor for diagnostic, therapeutic, or clinical applications. Use of GLP1-TZ outside laboratory research settings violates sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. §§ 355(a) and 331(d).

Product Specifications:

• Purity: >99% (HPLC verified)
• Formulation: Lyophilized powder for reconstitution
• Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular Weight: 4813.524 g/mol
• CAS Number: 2023788-19-2
• PubChem CID: 156588324
• Synonyms: Tirzepatide, P1206, LY3298176, BG 121, Dual GIP and GLP-1 receptor agonist (GIP/GLP-1RA)

Source: PubChem